Hepatitis Therapeutics Market

Hepatitis Therapeutics Market (Disease: Hepatitis A, Hepatitis B, Hepatitis C, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Hepatitis Therapeutics Market Outlook 2031

  • The industry was valued at US$ 16.0 Bn in 2022
  • It is estimated to grow at a CAGR of 3.6% from 2023 to 2031 and reach US$ 21.9 Bn by the end of 2031

Analyst Viewpoint

Rise in prevalence of hepatitis and R&D of new therapeutics are driving the hepatitis therapeutics market size. To control and completely eradicate hepatitis infections, this market offers a range of therapeutic alternatives such as immunomodulators, antiviral medications, and vaccinations.

Growth in awareness, better diagnostics, and technological developments in medicines are also boosting the hepatitis therapeutics industry demand.

R&D of new drugs is likely to offer lucrative hepatitis therapeutics market opportunities to vendors. Vendors are focused on the development of functional cures for the treatment of chronic hepatitis.

Leading molecules under development have entered clinical evaluation for the treatment of the disease.

Market Introduction

Hepatitis is defined by inflammation of the liver, which is typically brought on by viral infections. The term "hepatitis therapeutics" describes various approaches to manage and treat the condition.

These treatments seek to lessen liver damage and symptoms. Hepatitis treatment includes several antiviral medicines that can help fight the virus and slow its ability to damage the liver.

Entecavir (Baraclude), tenofovir (Viread), lamivudine (Epivir), adefovir (Hepsera), and telbivudine are some of the widely used hepatitis therapeutics. Tenofovir disoproxil fumarate (TDF) or entecavir (ETV) is the first-line oral therapy.

Attribute Detail
Drivers
  • Rise in Prevalence of Hepatitis
  • R&D of New Therapeutics

Rise in Prevalence of Hepatitis Propelling Hepatitis Therapeutics Market Value

Hepatitis is the inflammation of the liver, primarily caused by viral infections such as hepatitis A, B, and C. Amongst all of these, Hepatitis B is a highly prevalent virus that can cause severe liver cirrhosis and is considered to be extremely lethal.

Hepatitis B is the most prevalent acute liver infection in the world and a major concern to public health, additionally, it serves as the main cause of hepatocellular carcinoma, or HCC, the most common type of liver cancer and the second largest cause of cancer-related deaths worldwide. Thus, surge in prevalence of hepatitis is augmenting the hepatitis therapeutics market development.

According to a report by the Centers for Disease Control and Prevention (CDC), around 2,045 new cases of acute hepatitis B were reported in the U.S. in 2021, and around 14,229 cases of chronic hepatitis B were newly reported in 2021.

R&D of New Therapeutics Augmenting Market Progress

Governments and organizations across the globe are making efforts to increase awareness regarding hepatitis and its treatment.

Additionally, some governments are launching sponsored programs to encourage patients to accept hepatitis therapeutics which can reduce the prevalence of hepatitis. Such efforts are contributing to the hepatitis therapeutics market growth.

In 2023, Virion Therapeutics dosed the first patients in a Phase Ib trial investigating VRON-0200 as a functional cure for chronic Hepatitis B virus (HBV) infection.

The first-in-human study plans to enroll 48 patients at sites in Hong Kong and New Zealand. Such trials are focusing on functional treatment for hepatitis, thereby driving the hepatitis therapeutics market expansion.

Direct-acting antiviral (DAA) medications provide a more effective and direct method for hepatitis treatment as they are specially made to target the hepatitis virus's replicating mechanism. Since DAAs precisely target the proteins needed for HCV replication, they are more effective than prior treatments that attempted to treat the virus as a whole.

This makes them particularly helpful in treating the Hepatitis C virus (HCV). DAAs are usually taken in combination with two or three other medications to address the issue of HCV becoming resistant to single-drug therapy. Development and broad acceptance of DAA medications is fueling the hepatitis therapeutics market trajectory.

Regional Outlook

Attribute Detail
Leading Region North America

According to the latest hepatitis therapeutics market trends, North America held largest share in 2022. Rise in prevalence of hepatitis, government initiatives and strategic plans for hepatitis treatment, and implementation of cutting-edge treatment approaches are propelling the market dynamics of the region.

The Viral Hepatitis National Strategy Plan: 2021–2025 was released in the U.S. with the goals of enhancing data usage and surveillance, lowering disparities and health inequities, and improving health outcomes connected to viral hepatitis.

Presence of a well-established healthcare infrastructure, advantageous reimbursement policies, and increase in investment in research and development are also driving the hepatitis therapeutics market share in North America.

Analysis of Key Players

The global hepatitis therapeutics market landscape is highly competitive, with several opportunities for expansion and innovation. Major players are exploring personalized medicine in hepatitis therapeutics to revolutionize treatment approaches and improve patient outcomes.

Gilead Sciences, Inc., F. Hoffmann-La Roche, Ltd., Bristol Myers Squibb, Merck & Co., Inc., AbbVie Inc., NATCO Pharma Limited, Zydus Cadila, Hetero Healthcare Limited, LAURUS Labs, and Cipla, Inc. are some of the key players in this market.

Each of these companies has been profiled in the hepatitis therapeutics market report based on parameters such as company overview, business strategies, financial overview, business segments, product portfolio, and recent developments.

Key Developments

  • In December 2023, AstriVax was awarded €3.0 Mn in funding from Flanders Innovation & Entrepreneurship (VLAIO) for its therapeutic vaccine targeting chronic hepatitis B
  • In November 2022, Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) approved the supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients 12 years of age and older with compensated liver disease

Hepatitis Therapeutics Market Snapshot

Attribute Detail
Market Size in 2022 US$ 16.0 Bn
Market Forecast (Value) in 2031 US$ 21.9 Bn
Growth Rate (CAGR) 3.6%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy and recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • By Disease
    • Hepatitis A
    • Hepatitis B
    • Hepatitis C
    • Others
  • By Drug Class
    • Nucleotide Analog Reverse Transcriptase Inhibitor
    • NS5A Inhibitor
    • Multi-class Combination
    • Nucleotide Analog NS5B Polymerase Inhibitor
    • Interferon & Ribavirin
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa
Companies Profiled
  • Gilead Sciences, Inc.
  • F. Hoffmann-La Roche, Ltd.
  • Bristol Myers Squibb
  • Merck & Co., Inc.
  • AbbVie Inc.
  • NATCO Pharma Limited
  • Zydus Cadila
  • Hetero Healthcare Limited
  • LAURUS Labs
  • Cipla, Inc.
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global hepatitis therapeutics market in 2022?

It was valued at US$ 16.0 Bn in 2022

How is the hepatitis therapeutics business expected to grow by 2031?

It is anticipated to grow at a CAGR of 3.6% from 2023 to 2031

What are the key factors driving the demand for hepatitis therapeutics?

Rise in prevalence of hepatitis and R&D of new therapeutics

Which region provided higher business opportunities for hepatitis therapeutics in 2022?

North America provided higher business opportunities in 2022

Who are the prominent hepatitis therapeutics manufacturers?

Gilead Sciences, Inc., F. Hoffmann-La Roche, Ltd., Bristol Myers Squibb, Merck & Co., Inc., AbbVie Inc., NATCO Pharma Limited, Zydus Cadila, Hetero Healthcare Limited, LAURUS Labs and Cipla, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Hepatitis Therapeutics Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution/Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Hepatitis Therapeutics Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Product/Brand Analysis

        5.3. Key Mergers & Acquisitions

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Hepatitis Therapeutics Market Analysis and Forecast, by Disease

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Disease, 2017–2031

            6.3.1. Hepatitis A

            6.3.2. Hepatitis B

            6.3.3. Hepatitis C

            6.3.4. Others

        6.4. Market Attractiveness Analysis, by Disease

    7. Global Hepatitis Therapeutics Market Analysis and Forecast, by Drug Class

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Drug Class, 2017–2031

            7.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor

            7.3.2. NS5A Inhibitor

            7.3.3. Multi-class Combination

            7.3.4. Nucleotide Analog NS5B Polymerase Inhibitor

            7.3.5. Interferon & Ribavirin

            7.3.6. Others

        7.4. Market Attractiveness Analysis, by Drug Class

    8. Global Hepatitis Therapeutics Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Distribution Channel, 2017–2031

            8.3.1. Hospital Pharmacies

            8.3.2. Retail Pharmacies

            8.3.3. Online Pharmacies

        8.4. Market Attractiveness Analysis, by Drug Class

    9. Global Hepatitis Therapeutics Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region, 2017–2031

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Hepatitis Therapeutics Market Analysis and Forecast

        10.1. Introduction

        10.2. Key Findings

        10.3. Market Value Forecast, by Disease, 2017–2031

            10.3.1. Hepatitis A

            10.3.2. Hepatitis B

            10.3.3. Hepatitis C

            10.3.4. Others

        10.4. Market Value Forecast, by Drug Class, 2017–2031

            10.4.1. Nucleotide Analog Reverse Transcriptase Inhibitor

            10.4.2. NS5A Inhibitor

            10.4.3. Multi-class Combination

            10.4.4. Nucleotide Analog NS5B Polymerase Inhibitor

            10.4.5. Interferon & Ribavirin

            10.4.6. Others

        10.5. Market Value Forecast, by Distribution Channel, 2017–2031

            10.5.1. Hospital Pharmacies

            10.5.2. Retail Pharmacies

            10.5.3. Online Pharmacies

        10.6. Market Value Forecast, by Country, 2017–2031

            10.6.1. U.S.

            10.6.2. Canada

        10.7. Market Attractiveness Analysis

            10.7.1. By Disease

            10.7.2. By Drug Class

            10.7.3. By Distribution Channel

            10.7.4. By Country

    11. Europe Hepatitis Therapeutics Market Analysis and Forecast

        11.1. Introduction

        11.2. Key Findings

        11.3. Market Value Forecast, by Disease, 2017–2031

            11.3.1. Hepatitis A

            11.3.2. Hepatitis B

            11.3.3. Hepatitis C

            11.3.4. Others

        11.4. Market Value Forecast, by Drug Class, 2017–2031

            11.4.1. Nucleotide Analog Reverse Transcriptase Inhibitor

            11.4.2. NS5A Inhibitor

            11.4.3. Multi-class Combination

            11.4.4. Nucleotide Analog NS5B Polymerase Inhibitor

            11.4.5. Interferon & Ribavirin

            11.4.6. Others

        11.5. Market Value Forecast, by Distribution Channel, 2017–2031

            11.5.1. Hospital Pharmacies

            11.5.2. Retail Pharmacies

            11.5.3. Online Pharmacies

        11.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.6.1. Germany

            11.6.2. U.K.

            11.6.3. France

            11.6.4. Italy

            11.6.5. Spain

            11.6.6. Rest of Europe

        11.7. Market Attractiveness Analysis

            11.7.1. By Disease

            11.7.2. By Drug Class

            11.7.3. By Distribution Channel

            11.7.4. By Country/Sub-region

    12. Asia Pacific Hepatitis Therapeutics Market Analysis and Forecast

        12.1. Introduction

        12.2. Key Findings

        12.3. Market Value Forecast, by Disease, 2017–2031

            12.3.1. Hepatitis A

            12.3.2. Hepatitis B

            12.3.3. Hepatitis C

            12.3.4. Others

        12.4. Market Value Forecast, by Drug Class, 2017–2031

            12.4.1. Nucleotide Analog Reverse Transcriptase Inhibitor

            12.4.2. NS5A Inhibitor

            12.4.3. Multi-class Combination

            12.4.4. Nucleotide Analog NS5B Polymerase Inhibitor

            12.4.5. Interferon & Ribavirin

            12.4.6. Others

        12.5. Market Value Forecast, by Distribution Channel, 2017–2031

            12.5.1. Hospital Pharmacies

            12.5.2. Retail Pharmacies

            12.5.3. Online Pharmacies

        12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.6.1. China

            12.6.2. Japan

            12.6.3. India

            12.6.4. Australia & New Zealand

            12.6.5. Rest of Asia Pacific

        12.7. Market Attractiveness Analysis

            12.7.1. By Disease

            12.7.2. By Drug Class

            12.7.3. By Distribution Channel

            12.7.4. By Country/Sub-region

    13. Latin America Hepatitis Therapeutics Market Analysis and Forecast

        13.1. Introduction

        13.2. Key Findings

        13.3. Market Value Forecast, by Disease, 2017–2031

            13.3.1. Hepatitis A

            13.3.2. Hepatitis B

            13.3.3. Hepatitis C

            13.3.4. Others

        13.4. Market Value Forecast, by Drug Class, 2017–2031

            13.4.1. Nucleotide Analog Reverse Transcriptase Inhibitor

            13.4.2. NS5A Inhibitor

            13.4.3. Multi-class Combination

            13.4.4. Nucleotide Analog NS5B Polymerase Inhibitor

            13.4.5. Interferon & Ribavirin

            13.4.6. Others

        13.5. Market Value Forecast, by Distribution Channel, 2017–2031

            13.5.1. Hospital Pharmacies

            13.5.2. Retail Pharmacies

            13.5.3. Online Pharmacies

        13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.6.1. Brazil

            13.6.2. Mexico

            13.6.3. Rest of Latin America

        13.7. Market Attractiveness Analysis

            13.7.1. By Disease

            13.7.2. By Drug Class

            13.7.3. By Distribution Channel

            13.7.4. By Country/Sub-region

    14. Middle East & Africa Hepatitis Therapeutics Market Analysis and Forecast

        14.1. Introduction

        14.2. Key Findings

        14.3. Market Value Forecast, by Disease, 2017–2031

            14.3.1. Hepatitis A

            14.3.2. Hepatitis B

            14.3.3. Hepatitis C

            14.3.4. Others

        14.4. Market Value Forecast, by Drug Class, 2017–2031

            14.4.1. Nucleotide Analog Reverse Transcriptase Inhibitor

            14.4.2. NS5A Inhibitor

            14.4.3. Multi-class Combination

            14.4.4. Nucleotide Analog NS5B Polymerase Inhibitor

            14.4.5. Interferon & Ribavirin

            14.4.6. Others

        14.5. Market Value Forecast, by Distribution Channel, 2017–2031

            14.5.1. Hospital Pharmacies

            14.5.2. Retail Pharmacies

            14.5.3. Online Pharmacies

        14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.6.1. GCC Countries

            14.6.2. South Africa

            14.6.3. Rest of Middle East & Africa

        14.7. Market Attractiveness Analysis

            14.7.1. By Disease

            14.7.2. By Drug Class

            14.7.3. By Distribution Channel

            14.7.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

        15.2. Market Share Analysis, by Company (2022)

        15.3. Company Profiles

            15.3.1. Gilead Sciences, Inc.

                15.3.1.1. Company Overview

                15.3.1.2. Product Portfolio

                15.3.1.3. SWOT Analysis

                15.3.1.4. Financial Overview

                15.3.1.5. Strategic Overview

            15.3.2. F. Hoffmann-La Roche, Ltd.

                15.3.2.1. Company Overview

                15.3.2.2. Product Portfolio

                15.3.2.3. SWOT Analysis

                15.3.2.4. Financial Overview

                15.3.2.5. Strategic Overview

            15.3.3. Bristol Myers Squibb

                15.3.3.1. Company Overview

                15.3.3.2. Product Portfolio

                15.3.3.3. SWOT Analysis

                15.3.3.4. Financial Overview

                15.3.3.5. Strategic Overview

            15.3.4. Merck & Co., Inc.

                15.3.4.1. Company Overview

                15.3.4.2. Product Portfolio

                15.3.4.3. SWOT Analysis

                15.3.4.4. Financial Overview

                15.3.4.5. Strategic Overview

            15.3.5. AbbVie Inc.

                15.3.5.1. Company Overview

                15.3.5.2. Product Portfolio

                15.3.5.3. SWOT Analysis

                15.3.5.4. Financial Overview

                15.3.5.5. Strategic Overview

            15.3.6. NATCO Pharma Limited

                15.3.6.1. Company Overview

                15.3.6.2. Product Portfolio

                15.3.6.3. SWOT Analysis

                15.3.6.4. Financial Overview

                15.3.6.5. Strategic Overview

            15.3.7. Zydus Cadila

                15.3.7.1. Company Overview

                15.3.7.2. Product Portfolio

                15.3.7.3. SWOT Analysis

                15.3.7.4. Financial Overview

                15.3.7.5. Strategic Overview

            15.3.8. Hetero Healthcare Limited

                15.3.8.1. Company Overview

                15.3.8.2. Product Portfolio

                15.3.8.3. SWOT Analysis

                15.3.8.4. Financial Overview

                15.3.8.5. Strategic Overview

            15.3.9. LAURUS Labs

                15.3.9.1. Company Overview

                15.3.9.2. Product Portfolio

                15.3.9.3. SWOT Analysis

                15.3.9.4. Financial Overview

                15.3.9.5. Strategic Overview

            15.3.10. Cipla, Inc.

                15.3.10.1. Company Overview

                15.3.10.2. Product Portfolio

                15.3.10.3. SWOT Analysis

                15.3.10.4. Financial Overview

                15.3.10.5. Strategic Overview

    List of Tables

    Table 01: Global Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Disease, 2017–2031

    Table 02: Global Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 03: Global Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 04: Global Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Region, 2017–2031

    Table 05: North America Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Country, 2017–2031

    Table 06: North America Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Disease, 2017–2031

    Table 07: North America Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 08: North America Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 09: Europe Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Europe Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Disease, 2017–2031

    Table 11: Europe Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 12: Europe Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 13: Asia Pacific Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Asia Pacific Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Disease, 2017–2031

    Table 15: Asia Pacific Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 16: Asia Pacific Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 17: Latin America Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 18: Latin America Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Disease, 2017–2031

    Table 19: Latin America Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 20: Latin America Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 21: Middle East & Africa Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 22: Middle East & Africa Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Disease, 2017–2031

    Table 23: Middle East & Africa Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 24: Middle East & Africa Hepatitis Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    List of Figures

    Figure 01: Global Hepatitis Therapeutics Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031

    Figure 02: Global Hepatitis Therapeutics Market Revenue (US$ Mn), by Disease, 2022

    Figure 03: Global Hepatitis Therapeutics Market Value Share, by Disease, 2022

    Figure 04: Global Hepatitis Therapeutics Market Revenue (US$ Mn), by Drug Class, 2022

    Figure 05: Global Hepatitis Therapeutics Market Value Share, by Drug Class, 2022

    Figure 06: Global Hepatitis Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2022

    Figure 07: Global Hepatitis Therapeutics Market Value Share, by Distribution Channel, 2022

    Figure 08: Global Hepatitis Therapeutics Market Value Share, by Region, 2022

    Figure 09: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 10: Global Hepatitis Therapeutics Market Value Share Analysis, by Disease, 2022–2031

    Figure 11: Global Hepatitis Therapeutics Market Attractiveness Analysis, by Disease, 2020–2031

    Figure 12: Global Hepatitis Therapeutics Market Value Share Analysis, by Drug Class, 2022–2031

    Figure 13: Global Hepatitis Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2031

    Figure 14: Global Hepatitis Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 15: Global Hepatitis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2031

    Figure 16: Global Hepatitis Therapeutics Market Value Share Analysis, by Region, 2022–2031

    Figure 17: Global Hepatitis Therapeutics Market Attractiveness Analysis, by Region, 2020–2031

    Figure 18: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 19: North America Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2023–2031

    Figure 20: North America Hepatitis Therapeutics Market Value Share Analysis, by Country, 2022–2031

    Figure 21: North America Hepatitis Therapeutics Market Value Share Analysis, by Disease, 2022–2031

    Figure 22: North America Hepatitis Therapeutics Market Value Share Analysis, by Drug Class, 2022–2031

    Figure 23: North America Hepatitis Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 24: North America Hepatitis Therapeutics Market Attractiveness Analysis, by Disease, 2023–2031

    Figure 25: North America Hepatitis Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 26:North America Hepatitis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 27: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 28: Europe Hepatitis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

    Figure 29: Europe Hepatitis Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 30: Europe Hepatitis Therapeutics Market Value Share Analysis, by Disease, 2022–2031

    Figure 31: Europe Hepatitis Therapeutics Market Value Share Analysis, by Drug Class, 2022–2031

    Figure 32: Europe Hepatitis Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 33: Europe Hepatitis Therapeutics Market Attractiveness Analysis, by Disease, 2023–2031

    Figure 34: Europe Hepatitis Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 35: Europe Hepatitis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 36: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 37: Asia Pacific Hepatitis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 38: Asia Pacific Hepatitis Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 39: Asia Pacific Hepatitis Therapeutics Market Value Share Analysis, by Disease, 2022–2031

    Figure 40: Asia Pacific Hepatitis Therapeutics Market Value Share Analysis, by Drug Class, 2022–2031

    Figure 41: Asia Pacific Hepatitis Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 42: Asia Pacific Hepatitis Therapeutics Market Attractiveness Analysis, by Disease, 2023–2031

    Figure 43: Asia Pacific Hepatitis Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 44: Asia Pacific Hepatitis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 45: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 46: Latin America Hepatitis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 47: Latin America Hepatitis Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 48: Latin America Hepatitis Therapeutics Market Value Share Analysis, by Disease, 2022–2031

    Figure 49: Latin America Hepatitis Therapeutics Market Value Share Analysis, by Drug Class, 2022–2031

    Figure 50: Latin America Hepatitis Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 51: Latin America Hepatitis Therapeutics Market Attractiveness Analysis, by Disease, 2023–2031

    Figure 52: Latin America Hepatitis Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 53: Latin America Hepatitis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 54: Middle East & Africa Hepatitis Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 55: Middle East & Africa Hepatitis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 56: Middle East & Africa Hepatitis Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 57: Middle East & Africa Hepatitis Therapeutics Market Value Share Analysis, by Disease, 2022–2031

    Figure 58: Middle East & Africa Hepatitis Therapeutics Market Value Share Analysis, by Drug Class, 2022–2031

    Figure 59: Middle East & Africa Hepatitis Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 60: Middle East & Africa Hepatitis Therapeutics Market Attractiveness Analysis, by Disease, 2023–2031

    Figure 61: Middle East & Africa Hepatitis Therapeutics Market Attractiveness Analysis, by Drug Class, 2023–2031

    Figure 62: Middle East & Africa Hepatitis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Copyright © Transparency Market Research, Inc. All Rights reserved